Federal News
FTC Blocks Alcon-LENSAR Merger
March 16, 2026
The Federal Trade Commission (FTC) has intervened to stop the proposed merger between Alcon, Inc. and LENSAR, Inc., two leading manufacturers in the femtosecond laser-assisted cataract surgery (FLACS) device market. The FTC's Bureau of Competition determined that the merger would significantly reduce competition, potentially leading to higher prices and diminished innovation, adversely affecting surgeons and patients nationwide. This enforcement action preserves competitive dynamics and supports continued innovation and manufacturing jobs within the U.S. medical device sector.
- Why this matters: Procurement professionals in healthcare and medical device sectors should anticipate sustained competitive pricing and innovation opportunities in FLACS devices due to preserved market competition.
- The decision signals regulatory scrutiny on consolidation in specialized medical device markets, impacting vendor strategies and contract negotiations.
- Contractors and suppliers should evaluate how this enforcement action affects supply chain stability and potential partnership or bidding opportunities in ophthalmic surgical technologies.
- Agencies and healthcare providers can expect ongoing access to diverse FLACS device options, supporting procurement flexibility and cost management.
Agencies
Federal Trade Commission, Florida Attorney General's Office
Vendors
Alcon, Inc., Alcon Research, LLC, LENSAR, Inc.